15.20

1.11% -0.17

Innoviva Inc (INVA)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Innoviva Inc stock is currently priced at $15.20, with a 24-hour trading volume of 424.05K. It has seen a -1.11% decreased in the last 24 hours and a +2.63% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $15.28 pivot point. If it approaches the $15.18 support level, significant changes may occur.

Previous Close:

$15.37

Open:

$15.53

24h Volume:

424.05K

Market Cap:

$950.28M

Revenue:

$310.46M

Net Income/Loss:

$179.72M

P/E Ratio:

6.7257

EPS:

2.26

Net Cash Flow:

$140.65M

1W Performance:

-0.39%

1M Performance:

+2.63%

6M Performance:

+11.52%

1Y Performance:

+31.83%

1D Range:

$15.13

$15.63

52W Range:

$11.40

$16.86

Innoviva Inc Stock (INVA) Company Profile

Name

Innoviva Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

650-238-9600

Address

2000 Sierra Point Parkway, Suite 500, Brisbane

Employee

Twitter

Next Earnings Date

2024-05-07

Latest SEC Filings

INVA's Discussions on Twitter

Innoviva Inc Stock (INVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-20-22	Initiated	Goldman	Neutral
Nov-20-17	Initiated	Deutsche Bank	Hold

Innoviva Inc Stock (INVA) Latest News

Innoviva Inc Stock (INVA) Financials Data

Innoviva Inc (INVA) Revenue 2024

INVA reported a revenue (TTM) of $310.46 million for the quarter ending December 31, 2023, a -6.30% decline year-over-year.

Innoviva Inc (INVA) Net Income 2024

INVA net income (TTM) was $179.72 million for the quarter ending December 31, 2023, a -15.99% decrease year-over-year.

Innoviva Inc (INVA) Cash Flow 2024

INVA recorded a free cash flow (TTM) of $140.65 million for the quarter ending December 31, 2023, a -30.25% decrease year-over-year.

Innoviva Inc (INVA) Earnings per Share 2024

INVA earnings per share (TTM) was $2.18 for the quarter ending December 31, 2023, a +7.39% growth year-over-year.

Innoviva Inc Stock (INVA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
DENNER ALEXANDER J	10% Owner	Jun 06 '23	Buy	13.05	8,000	104,384	7,215,000
DENNER ALEXANDER J	10% Owner	Jun 05 '23	Buy	13.04	7,000	91,297	7,207,000
DENNER ALEXANDER J	10% Owner	May 30 '23	Buy	13.01	120,000	1,560,648	7,200,000
DENNER ALEXANDER J	10% Owner	May 26 '23	Buy	13.12	30,000	393,729	7,080,000
DENNER ALEXANDER J	10% Owner	May 25 '23	Buy	13.09	50,000	654,330	7,050,000
DENNER ALEXANDER J	10% Owner	May 18 '23	Buy	13.05	10,000	130,538	6,964,000
DENNER ALEXANDER J	10% Owner	May 17 '23	Buy	13.07	50,000	653,690	6,954,000
DENNER ALEXANDER J	10% Owner	May 11 '23	Buy	12.34	290,000	3,577,411	6,904,000

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.